-
Mashup Score: 0
Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Adjuvant #pembrolizumab led to a significant and clinically meaningful improvement in overall survival vs placebo in patients with clear-cell renal cell carcinoma, according to findings from #KEYNOTE-564. #KCSM | @DrChoueiri @tompowles1 https://t.co/iBw7DX099Z